Stockscreener 앱 받기
3.13
1.88%
-0.06
시간 외 거래:
3.11
-0.02
-0.64%
Wave Life Sciences Ltd 주식(WVE)의 최신 뉴스
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Form 4 Wave Life Sciences For: 10 October By Investing.com - Investing.com South Africa
Form 4 Wave Life Sciences For: 7 October By Investing.com - Investing.com Nigeria
Wave Life Sciences Director Christian Henry Awarded 10,700 RSUs and 64,000 Stock Options - Kalkine Media
A director receives a 10,700-share stock grant plus options at Wave Life Sciences (WVE). - Stock Titan
A director receives a 10,700-share stock grant and 64,000-share option at Wave Life Sciences (WVE). - Stock Titan
A director receives 10,700 stock units and a 64,000-share option at Wave Life Sciences (WVE). - Stock Titan
A 10,700-share stock grant joins 64,000 options for Wave Life Sciences (WVE) director Ken Takanashi. - Stock Titan
Wave Life Sciences Director Adrian Rawcliffe Awarded 10,700 RSUs and 64,000 Stock Options in 2026 Equity Grants - Kalkine Media
How Is GSK (LSE:GSK) Stock Reacting This Week To Its Wave Life Sciences Liver Candidate? - Kalkine Media
FDA supports a one-year data check for possible faster approval of Wave's treatment. - Stock Titan
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - TradingView
Wave Life Sciences stock hits a 52-week low at USD 4.20 - AD HOC NEWS
Wave Life Sciences Names Monika Vnuk Chief Business Officer - citybiz
Wave Life Sciences appoints Monika Vnuk as chief business officer By Investing.com - Investing.com Australia
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - The Manila Times
Wave Life Sciences Appoints Monika Vnuk as Chief Business Officer - Quiver Quantitative
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - Yahoo Finance
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com Nigeria
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com Canada
Wave Life Sciences at Cantor conference: RNA editing gains traction - investing.com
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com UK
Wave Life Sciences stock holds steady ahead of Cantor healthcare conference appearance - ad-hoc-news.de
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference - GlobeNewswire
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference - Yahoo Finance
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Wave Life Sciences stock trades quietly as investors focus on recent clinical progress - ad-hoc-news.de
WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold" - MarketBeat
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - Simply Wall Street
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - simplywall.st
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - simplywall.st
Wave Life Sciences targets fat loss without sacrificing muscle - Longevity.Technology
Insiders Sold Wave Life Sciences Prematurely At US$13.64 With Stock Trading Higher - Moomoo
Wave Life Sciences (WVE) Pulls Back 5.2% to $5.13 as Support Holds at $4.87Thematic ETF Flow - vinanet.vn
Wave Life Sciences Ltd. SEC Filing (Aug 17, 2026) - Stock Titan
Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones - Stock Traders Daily
Wave Life Sciences, Inc.: Top Mutual Funds Holders | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Target Price Consensus and Analysts Recommendations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Performance & Quotes, WVE Stock Price on Nasdaq Exchange - marketscreener.com
Wave Life Sciences, Inc.: Fundamental Analysis and Financial Ratings | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Financial Data Forecasts Estimates and Expectations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc. Stock (WVE)Quote Nasdaq - marketscreener.com
Q1 2025 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
WAVE Life Sciences Ltd at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Q2 2026 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
Wave Life Sciences Ltd.: Revenue and Earnings Analysts Forecasts Revisions | WVE | US94352A1043 - marketscreener.com
WVE Q2 2026 Earnings: Wider-than-Expected Loss of $0.34 per Share Highlights Pipeline InvestmentProfit Growth Outlook - https://www.dars.gov.et/
Wave Life Sciences (WVE) Director Adrian Rawcliffe Sells 12,700 Shares, Reducing Stake to Zero - GuruFocus
1.74%
자본화:
|
볼륨(24시간):